|Articles|August 9, 2019
COA Applauds CMS' Decision on CAR T-Cell Therapy
Following CMS’ decision to make chimeric antigen receptor (CAR) T-cell therapy available to Medicare beneficiaries nationwide, including in the community oncology setting, the Community Oncology Alliance (COA) applauded the decision.
Advertisement
Following CMS’ decision to make chimeric antigen receptor (CAR) T-cell therapy available to Medicare beneficiaries nationwide, including in the community oncology setting, the Community Oncology Alliance (COA) applauded the decision. According to COA, the agency listened to the feedback of community practices by ensuring that CAR T-cell therapy is covered outside of the hospital setting.
COA is also pleased that by protecting Medicare beneficiaries, the agency has streamlined the reporting requirements and aligned requirements between CMS and the FDA, which will reduce burden for providers, Medicare, and patients.
Read the full press release .
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- Trends in RNA Therapeutic Research
September 8th 2025
- The Therapeutic Potential of Circular RNA
September 7th 2025
- CGTLive®’s Weekly Rewind – September 5, 2025
September 5th 2025
Advertisement
Advertisement